| Mrs Sigrun Hallmeyer, MD | |
|
1700 Luther Ln # 2200, Park Ridge, IL 60068-1270 | |
| (847) 268-8200 | |
| (847) 318-2905 |
| Full Name | Mrs Sigrun Hallmeyer |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 26 Years |
| Location | 1700 Luther Ln # 2200, Park Ridge, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164481412 | NPI | - | NPPES |
| 036106308 | Medicaid | IL | |
| K21580 | Other | IL | PIN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 036106308 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Advocate Illinois Masonic Medical Center | Chicago, IL | Hospital |
| Advocate Lutheran General Hospital | Park ridge, IL | Hospital |
| Advocate Good Shepherd Hospital | Barrington, IL | Hospital |
| Advocate Condell Medical Center | Libertyville, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advocate Health And Hospitals Corporation | 7810800935 | 2422 |
News Archive
This new advanced automated stainer offers significant improvements in workflow optimization, particularly when multiple protocols are used. It has been intelligently designed to be easier to use than ever, with a new touch screen interface and intuitive software.
Stringent lockdown measures imposed in the spring of 2020 led to a dramatic drop in vaccinations among both children and adults, according to a new study led by Children's Hospital of Philadelphia.
While cities have shown considerable racial disparities in cancer survival, those racial disparities virtually disappear among smaller populations, such as neighborhoods within that city.
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.
› Verified 4 days ago
| Entity Name | Advocate Health And Hospitals Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700824455 PECOS PAC ID: 7810800935 Enrollment ID: O20031106000064 |
News Archive
This new advanced automated stainer offers significant improvements in workflow optimization, particularly when multiple protocols are used. It has been intelligently designed to be easier to use than ever, with a new touch screen interface and intuitive software.
Stringent lockdown measures imposed in the spring of 2020 led to a dramatic drop in vaccinations among both children and adults, according to a new study led by Children's Hospital of Philadelphia.
While cities have shown considerable racial disparities in cancer survival, those racial disparities virtually disappear among smaller populations, such as neighborhoods within that city.
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Sigrun Hallmeyer, MD Po Box 736, Park Ridge, IL 60068-0736 Ph: (847) 268-8200 | Mrs Sigrun Hallmeyer, MD 1700 Luther Ln # 2200, Park Ridge, IL 60068-1270 Ph: (847) 268-8200 |
News Archive
This new advanced automated stainer offers significant improvements in workflow optimization, particularly when multiple protocols are used. It has been intelligently designed to be easier to use than ever, with a new touch screen interface and intuitive software.
Stringent lockdown measures imposed in the spring of 2020 led to a dramatic drop in vaccinations among both children and adults, according to a new study led by Children's Hospital of Philadelphia.
While cities have shown considerable racial disparities in cancer survival, those racial disparities virtually disappear among smaller populations, such as neighborhoods within that city.
BioMarin Pharmaceutical Inc. today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and issued a notice of acceptance for the Phase 3 trial of N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Mucopolysaccharidosis IVA (MPS IVA). The company expects to initiate the Phase 3 pivotal trial early in the first quarter of 2011.
Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.
› Verified 4 days ago
Dr. Jason Nathaniel Macklis, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1700 Luther Ln Ste 2200, Park Ridge, IL 60068 Phone: 847-268-8577 | |
Mohammed Omer Ahmed Abdalla, Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 850 Busse Hwy, Park Ridge, IL 60068 Phone: 847-759-4770 | |
Nayana P Dave, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1775 Dempster St Ste E592b, Park Ridge, IL 60068 Phone: 847-723-8080 | |
Dr. Anand Ramadorai, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1550 N Northwest Hwy Ste 303, Park Ridge, IL 60068 Phone: 847-294-5160 | |
Dr. Patrick J Murphy, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 711 W Devon, Park Ridge, IL 60068 Phone: 847-696-3176 Fax: 847-696-2678 | |
Dr. Peter Vayalil, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1775 Dempster St Ste E592b, Park Ridge, IL 60068 Phone: 847-723-8080 | |
William D. Rhoades, D.O. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1775 Ballard Rd, Park Ridge, IL 60068 Phone: 847-318-2500 |